Earnings ·
Theriva Biologics reported financial results for the quarter ended June 30, 2026
TOVXTheriva Biologics, Inc.
Theriva Biologics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $5.3 million for the six-month period and held cash and cash equivalents of $11.3 million as of June 30, 2026, providing a runway into Q1 2027. General and administrative expenses decreased to $2.0 million from $11.2 million in the prior year period, primarily due to a $9.2 million reduction in fair value adjustments for contingent consideration related to VIRAGE Phase 2b trial results. Research and development expenses fell to $1.3 million from $2.0 million. The company dosed the first patients in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 for metastatic pancreatic ductal adenocarcinoma, with enrollment expected to complete in H2 2026 and initial data anticipated by Q3 2027. Theriva Biologics is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.